Diagnostic effectiveness of Chromogranin A and multigene liquid biopsy (NETest) in neuroendocrine neoplasia: A prospective comparative evaluation of monoanalyte and multianalyte biomarker efficacy

#3200

Introduction: The absence of a reliable, universal biomarker is a significant limitation in neuroendocrine neoplasia (NEN) management.

Aim(s): We prospectively evaluated two CgA assays (NEOLISA, EuroDiagnostica,) and (CgA ELISA, Demeditec Diagnostics (DD)), and compared the results to the NETest.

Materials and methods: NEN cohort (n=258): pancreatic, n=67; small intestine, n=40; appendiceal, n=10; rectal, n=45; duodenal, n=9; gastric, n=44; lung, n=43. Image-positive disease (IPD) (n=123), image & histology negative (IND) (n=106), and image negative & histology positive (n=29). CgA metrics: NEOLISA, ULN: 108ng/mL, DD: ULN: 99ng/mL. Data mean±SEM. NETest: qRT-PCR - multianalyte analyses, ULN: 20. All samples de-identified and assessed blinded. Statistics: Mann-Whitney U-test, Pearson correlation & McNemar-test.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Malczewska A

Authors: Malczewska A, Oberg K, Kos-Kudla B,

Keywords: CgA, NETest, diagnostic, biomarker, NEN, genomic analysis, elisa,